Novo Nordisk said that the science of blockbuster obesity drugs will explore how patients who are struggling with addiction.
The GLP-1 drugs in the market include Zepbound, which is a novo nordisk diabetes drug ozempic, weight loss treatment Wegovy and ELI Lilly’s obesity drugs.
However, by controlling blood sugar levels and causing full feelings, the type of drugs that work effective is investigating whether it can improve health in different ways.
Lange said, “We will look at this further and potentially explore how to help with addiction patients with GLP-1.
“It must be solved in a very strict way from a regulatory point of view, so we can actually see the potential effects of GLP-1 in that space.”
NOVO NORDISK’s commercial strategy and vice president of business business, Ireland Times exclusively, Camilla Sylvest said it will pursue it if there is evidence that the Semaglutide drug, the active ingredients of Ozempic and Wegovy, can contribute to health.
“From the point of view of Martin’s longing for craving, there may be a signal that this can be interesting,” she said.
“Retailers are currently increasing rapidly”: BWG Group’s former CEO Leo Crawford
One of the methods of GLP-1 pharmaceutical action is to activate the brain receptor that controls the feeling of hunger and hunger to reduce hunger and hunger. The question is whether or not you can do the same as the craving of addiction.
Sylvest pointed out the results of the trial of GLP-1 on the progress of Alzheimer’s disease at the end of this year. “A few years ago, a few years ago, we pointed out that the company started trial when we signed a signal that people in GLP-1 in the registry showed a slower development of Alzheimer’s than those who did not treat GLP-1. We thought it was our duty to pursue this more.
“In addiction, we can see the signal that three hemp glue tides can be beneficial in that direction, so it is a similar situation considering investigating it. But this is still early. ”She warned. -A addition, Reuters
